Login to Your Account

Survey: Low Awareness of HTA Rules Hurt European Biotechs

By Nuala Moran
Staff Writer

Wednesday, April 11, 2012
LONDON – Europe's small biotechs are finding it very hard to cross the health technology assessment (HTA) barriers that governments are erecting to test the cost benefits of new drugs, according to a survey carried out by the industry body EuropaBio.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription